Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Technical Know How
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 147899
The Licensor and the Licensee have collaborated in a research effort directed at certain serotonin (5- hydroxytryptamine or 5-HT) receptors and 5-HT-related disorders. Receptors are targets for the treatment of GI motility disorders.
'5-HT4 Receptor' means any 5-HT4 receptor that is disclosed in U.S. Letters Patent No. 5,472,866 entitled 'DNA Encoding 5-HT4a Receptors' and PCT International Application entitled 'DNA Encoding 5-HT4 Serotonin Receptors and Uses Thereof,' published as WO 94/14957.
IPSCIO Record ID: 328170
Modification of Definition for Project
Project means (i) with respect to the period beginning on January 25, 1991, and ending on December 31, 1994, the research and development program conducted by Licensor in the Field in collaboration with Licensee during such period and (ii) with respect to the period beginning on January 1, 1995, the continuation of such program; provided, however, that from and after January 1, 1995, such program shall be limited to the continued provision by Licensor to Licensee of support in (A) the evaluation by Licensor of Licensee Compounds at Project Receptors and at the 5-HT4 Receptors in binding and functional assays, (B) tissue localization studies involving Project Receptors. (C) the conduct of neurotransmitter release studies involving Project Receptors and 5-HT4 Receptors and (D) the identification of new species homologues of Project Receptors, all in accordance with Sections 2.00, 2.01 and 5.00 and to the extent that Licensees license shall not have terminated pursuant to Section 6.02; provided further, however, that such program may be expanded to include Licensor chemistry resources as contemplated by section 7.00.
Addition of New Defined Terms
Library Compound means any Existing Licensee Compound or New Compound included within a Licensee Library.
Licensee Library means any compound library which (i) Licensee, or an Affiliate thereof, owns or otherwise has access to and (ii) is subject to high volume screening in assays using Existing Licensor Technology, Project Technology and/or 5-HT4 Receptors at Licensees Affiliate, Sphinx Pharmaceuticals, or at other mutually agreed sites.
5-HT4 Receptor means any 5-HT4 receptor that is disclosed in U.S. Letters Patent No. 5,472,866 entitled 'DNA Encoding 5-HT4a Receptors' and PCT International Application entitled 'DNA Encoding 5-HT4 Serotonin Receptors and Uses Thereof,' published as WO 94/14957.
U.S. 5,472,866 – DNA encoding 5-HT.sub.4A serotonin receptors
Amended section From January 1, 1995, through December 31, 1996, Licensor shall devote a minimum of ten Scientific Man Years per year to the Project. From and after January 1, 1997, during the term of the Project, Licensor shall devote a minimum of twenty-two Scientific Man Years per year to the Project, at least four of which shall be provided by scientists with Ph.D. degrees.
IPSCIO Record ID: 328352
Project Compound means any chemical entity which interacts directly with an ob Gene-related Target and which already exists or which is synthesized, identified or licensed by Licensee and/or Licensor, either jointly or independently, and the further development of which for a Project Use is commenced by Licensee during the Project Term or the Post-Project Term.
Assay means a proprietary assay for any ob Gene-related Target or combination of such Targets which exists at the Effective Date, or which is developed during the term of this Agreement as part of the Project and which can be employed to screen compounds for their ability to interact directly with ob Gene-related Targets.
Project Use means and includes the treatment in humans of eating or metabolic disorders, or obesity, and/or the diagnosis of any such disorders or conditions.
IPSCIO Record ID: 328171
For the Licenses, Licensor grants throughout the territory, for the sole purpose of developing, making, having made, using and selling selective Alpha-1 an Adrenergic Receptor Products which are not BPH Products, a non-exclusive license under any of the Receptor patents. The section of the license grant shall extend back in time to apply to acts by Licensee prior to the Effective Date of this agreement.
Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Receptor Patents.
Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Functional Use Patents.
Upon exercise of the Option, Licensor grants throughout the Territory, for the sole purpose of developing, making, having made, using and selling BPH Products a non-exclusive license under the Patents.
BPH Compound shall mean any Selective Alpha-1a Adrenergic Receptor Compound for which regulatory approval to sell for the treatment of BPH or for the inhibition of contraction of prostate tissue has been obtained or is being sought.
BPH Product shall mean any prescription or over-the-counter pharmaceutical preparation containing BPH Compounds for use in humans.
Human Alpha-1 Adrenergic Receptors shall mean alpha-1a , alpha-1b, and, alpha-1d.
Selective Alpha-1 Adrenergic Receptor Product shall mean any prescription or over-the-counter pharmaceutical preparation containing Selective Alpha-1a Adrenergic Receptor Compounds for use in human or non-human animals.
The Therapeutic indication shall mean, with respect to any Selective Alpha-1a Adrenergic Receptor Product, the main therapeutic use as classified in the 2nd level of the World Health Organization Anatomical, Therapeutic, Clinical (ATC) drug classification system.
Licensee is developing selective human alpha-1a adrenergic receptor compounds which may be useful for the treatment of BPH and other medical conditions and is using cloned human alpha-1 adrenergic receptors.
IPSCIO Record ID: 329676
For the license grant for Non-Exclusive Screens, License grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice Non-Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee, during the term of the Research Programs, but in no event for less than nine months after Licensee receives Materials and other information from Licensor identifying and enabling Licensee to use such Non-Exclusive Screen.
The Autocrine System shall mean that part of Licensors Technology whereby any yeast cells into which human Receptors have been inserted and grow in response to compounds produced and secreted by the same yeast cells.
Compound shall mean any Lead Compound or any Analog of any Lead Compound.
Receptor shall mean any human, G-protein-coupled, seven transmembrane receptor (including, without limitation, genes, vectors and cDNAs), and shall include any Licensee Receptor or Other Receptor.
Licensee Receptor shall mean a Receptor which is proprietary to Licensee and is provided by Licensee to Licensor for use in the Research Programs, or a Receptor which is proprietary to Licensee and is cloned or obtained by Licensor pursuant to research performed under the Research Programs, or a Receptor provided by Licensee to Licensor for use in the Research Programs which is deemed to be a Licensee Receptor.
Technology shall mean all inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, Patents and Know-How owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses, and relating to or derived from Licensors yeast-based, human G-protein-coupled receptor technology, or the Research Programs.
The Patents are titled
Expression of G Protein Coupled Receptors in Yeast, Yeast-Based Peptide Libraries for identification of G Protein-Coupled Receptor Agonists and Antagonists, and, Functional Expression of Mammalian Adenylyl cyclase in Yeast.
Licensee recognizes that the technology represents a valuable source of development of screening assays for the discovery of potential products for manufacture, use and sale in the Territory.